

## Supplementary material

**Table S1. Search strategy**

Database	Dates	Search terms
Medline	1946 –18 <sup>th</sup> April 2016	<ol style="list-style-type: none"> <li>1. Medication Adherence/</li> <li>2. Patient Compliance/</li> <li>3. (adher* or complian*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</li> <li>4. (persist* or discontin*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</li> <li>5. 1 or 2 or 3 or 4</li> <li>6. Tamoxifen/</li> <li>7. tamoxifen.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</li> <li>8. aromatase inhibitors/</li> <li>9. aromatase inhibitor*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</li> <li>10. Endocrine therapy.mp</li> <li>11. Hormon* therapy.mp</li> <li>12. 6 or 7 or 8 or 9 or 10 or 11</li> <li>13. Breast Neoplasms/</li> <li>14. Breast cancer*.mp</li> <li>15. breast neoplasm*.mp</li> <li>16. 13 or 14 or 15</li> <li>17. 5 and 12 and 16</li> <li>18. Limit 17 to female</li> </ol>
Psychinfo	1806 –18 <sup>th</sup> April 2016	<ol style="list-style-type: none"> <li>1. Exp Treatment compliance/</li> <li>2. (adher* or complian*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>3. Exp Treatment Termination/</li> <li>4. (persist* or discontin*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>5. 1 or 2 or 3 or 4</li> <li>6. Exp Hormone therapy/</li> <li>7. tamoxifen.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>8. endocrine therapy.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>9. aromatase inhibitor*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>10. hormon* therapy.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>11. 6 or 7 or 8 or 9 or 10</li> <li>12. Exp breast neoplasm/</li> <li>13. (breast cancer* or breast neoplasm*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests &amp; measures]</li> <li>14. 12 or 13</li> <li>15. 5 and 11 and 14</li> <li>16. Limit 15 to female</li> </ol>
Embase	1974 - 18 <sup>th</sup> April 2016	<ol style="list-style-type: none"> <li>1. Patient compliance/</li> <li>2. (persist* or discontin*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</li> <li>3. (adher* or complian*).mp. [mp=title, abstract, subject headings,</li> </ol>

		heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
		4. 1 or 2 or 3
		5. Tamoxifen/ or tamoxifen.mp.
		6. Aromatase inhibitor/
		7. Hormonal therapy/
		8. aromatase inhibitor*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
		9. hormon* therapy.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
		10. endocrine therapy.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
		11. 5 or 6 or 7 or 8 or 9 or 10
		12. Breast cancer/
		13. (breast neoplasm* or breast cancer*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
		14. 12 or 13
		15. 4 and 11 and 14
		16. Limit 16 to female
Web of Science	Up to 18 <sup>th</sup> April 2016	1. Adher* or complian*
		2. Persist* or discontin*
		3. 1 or 2
		4. Tamoxifen
		5. Aromatase inhibitor*
		6. Hormon* therapy
		7. Endocrine therapy
		8. 4 or 5 or 6 or 7
		9. breast cancer* or breast neoplasm*
		10. 3 and 8 and 9
CINAHL	Up to 18 <sup>th</sup> April 2016	1. (MH "Medication Compliance") OR (MH "Patient Compliance")
		2. adher* or complian* or persist* or discontin*
		3. 1 or 2
		4. (MH "Tamoxifen") OR (MH "Aromatase Inhibitors") OR (MH "Hormone Therapy")
		5. Tamoxifen OR Aromatase inhibitor* OR Hormon* therapy OR Endocrine therapy
		6. 4 or 5
		7. (MH "Breast Neoplasms")
		8. Breast cancer* or breast neoplasm*
		9. 7 or 8
		10. 3 and 6 and 9

---

